TIGIT and ovarian cancer: Findings indicate that NK cells derived from patients with advanced ovarian cancer typically exhibit a markedly immunosuppressive phenotype, whereas targeted TIGIT blockade specifically enhances the effector functions of the CD56dim NK cell subset [194].